R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
